Because tumor-associated myeloid cells, including macrophages, DCs, and MDSCs, express adenosine-binding receptors (AR), they are potential targets of AR blockers, which may enhance immune reactions against tumor cells [63]. The gene discussed is AR; the disease is neoplasm.